What Are CJC 1295 and Ipamorelin? How They Work + What To Expect

Watch the full video on Rumble: https://rumble.com/v7g3hw2-what-are-cjc-1295-and-ipamorelin-how-they-work-what-to-expect.html

If you've been looking at a peptides like CJC1295 and ipomerelin, you've probably heard people say that they can help with recovery, fat loss, and even better sleep. That reputation is mostly earned, but it gets earned slowly, and understanding why requires walking the whole chain from your brain down to your liver before we zoom in on any single piece of it.

Your hypothalamus releases a signal, your pituitary responds by releasing growth hormone in a burst, that burst travels to your liver, and your liver produces the molecule that actually goes out and changes your tissue. Nothing in that chain is a single switch. It is a relay, and each of these two peptides is inserting itself at a different point in the relay.

CJC1295 is a lab-made version of a hormone your brain already produces called GHRH, or growth hormone releasing hormone. Your hypothalamus makes GHRH, sends it a very short distance to the pituitary, and the pituitary opens up.

CJC1295 mimics that switch. It binds the same receptor, and the pituitary does not know the difference.

Now, there are two versions of CJC1295, with DAC and without DAC. DAC stands for drug affinity complex, which is a small chemical addition designed to keep the molecule in circulation far longer than the unmodified version.

The practical difference is dosing frequency and the shape of the curve you end up with. From what I have seen, the with-DAC version lets people inject once or twice a week and hold an elevated baseline, and the without-DAC version requires multiple daily injections to keep pulses going, though I cannot point you to a study that gives you clean human half-life numbers for either one at the doses people actually run.

With DAC is like a slow-release capsule, and no DAC is like a quick-release pill. One buys you convenience, the other buys you control over exactly when the signal fires.

On a completely different receptor, ipomerelin gets to work in the pituitary through the ghrelin receptor system, and what comes out the other end is a short, sharp release of growth hormone rather than a raised floor. I have seen this described as binding directly in the pituitary gland, and the receptor-level detail is not something I can hand you a human study on.

There are older peptides in this family, like GHRP2 and GHRP6, which also worked on ghrelin receptors, but they came with baggage. They spiked your cortisol, which is your stress hormone, and prolactin, which can cause unwanted side effects like low libido or breast tissue changes in men. The numbers back this up. When Arvat and colleagues gave GHRP-2 to healthy people, it raised prolactin, ACTH and cortisol alongside growth hormone, and a follow-up study from the same group found the same endocrine profile with hexarelin and its analogs [Arvat 1997; Arvat 1999].

Ipamorelin was built specifically to lose that baggage. Raun and colleagues characterized it as the first selective growth hormone secretagogue, releasing growth hormone without the ACTH and cortisol response that the earlier compounds produced [Raun 1998]. On the prolactin question specifically, I have not seen problems in clients, but no study has shown me a clean human prolactin dataset I would hang a promise on.

That selectivity is the whole reason it ended up as the default partner peptide. On its own it gives you clean bursts. But when you combine it with something like CJC1295, it amplifies that baseline signal and makes this whole system work much more like it did when you were younger.

Think of CJC1295 as setting the volume and ipomerelin as adding the rhythm.

Together, you get a pattern that looks a lot like your natural growth hormone release when you were in your 20s.

Most people skip straight past the next link in the chain, and if you stop your mental model at growth hormone you will misjudge everything about the timeline, because growth hormone does not build muscle by itself.

What it does is signal your liver to produce something called IGF1, or insulin-like growth factor one. The liver is where the message gets converted into something that acts on tissue, and animal work shows how tightly coupled the two are: when liver-derived IGF-1 drops in food-restricted mice, growth hormone secretion itself gets rewired in response [de Sousa 2025].

IGF1 is what is usually described as driving recovery, muscle repair, collagen growth and fat mobilization, though I would tell you honestly that the research hasn't given us clean human trials tying peptide-driven IGF1 rises to each of those specific outcomes.

Growth hormone is the coach shouting instructions from the sideline, and IGF is actual players out on the field executing the plays.

So when you raise your growth hormone with CJC and ipomerelin, what you're really doing is raising IGF1 passively, and that's what creates the changes you feel.

The amount you raise it by is only half the story, because when it happens carries just as much weight. Your body pulses growth hormone hardest during deep sleep and after hard training, and that's exactly when the IGF1 gets activated and does its best work, repairing muscle tissue, burning fat, and helping you recover.

Flatten that curve with direct growth hormone injections and you lose the rhythm your tissue is built around. You also inherit the problems that come with chronically elevated growth hormone, and insulin resistance is the clearest one, which is why secondary diabetes shows up as a recognized complication in acromegaly, the condition of persistently high growth hormone [Moustaki 2023].

A few other peptides round out this family, worth knowing even if you never touch them. Sermerelin is older and shorter acting, and tessamerelin has been studied for visceral fat in HIV patients. But ipomerelin is generally considered the cleanest and the most effective of the three, which is why it's usually the go-to when people add it to CJC. Now, I'll break sermerelin and tessamerelin down in future videos, but just know ipomerelin is the one most people stick with, especially for stacking.

The benefits arrive in a fixed order, and knowing the order is what keeps people from quitting at week three.

Within the first week or two, you're experiencing deeper sleep, waking up more rested, and that's pretty big because that deep sleep is when your body naturally pumps out the most growth hormone, and that's when you're recovering from your training.

Recovery follows at roughly two to four weeks. Less soreness, better training quality, less of that afternoon drag.

Around the eight to 12-week mark, you're probably gonna notice that you're leading out more efficiently, but keep in mind this isn't magic. Diet and training still do the heavy lifting.

And the last benefit is collagen and joint health, and that's really the longer play that you're probably not gonna experience for months three to six. But when you do, you'll notice a significant improvement in how your skin tendons and joints feel on a day-to-day basis, and this is huge for guys who are over 40, especially the ones with knee, hip, and lower back pain.

I ran the blend for three months myself and the sleep change was obvious while the muscle and strength changes were negligible, though I am already on TRT, which changes the equation.

For my clients who took it, the two biggest things that they noticed were also better sleep, and a lot of them reported much more efficient fat loss when using the stack consistently, but these guys were on it for 16 to 24 weeks and really didn't realize those benefits until towards the end of their cycle.

Most people get off easy here. Injection site redness or itching, flushing, a headache, some water retention. Some people also reported increased hunger, which is usually synonymous with increases in growth hormone, especially if your dosing isn't dialed in, but with ipomerelin, that's less of an issue compared to other peptides like somerelin or tussomerelin.

Push the dose too high and you get numbness in the hands, carpal tunnel symptoms, swelling in the face and joints. That is your body telling you to back off.

If you have cancer or a history of cancer, you absolutely should not take these drugs. Growth hormone and IGF-1 can accelerate tumor growth, and that's pretty much a non-negotiable for you.

We also do not have decades of safety data on these compounds, and that absence is a real thing to weigh rather than a formality.

There is a lot more of this inside the free community, and it is genuinely free, so if you want somewhere to ask the follow-up question the men's group is here: https://www.skool.com/jh-iron-forge-brotherhood/about

Research: Raun 1998, Eur J Endocrinol; Arvat 1997, Peptides; Arvat 1999, J Endocrinol Invest; de Sousa 2025, Endocrinology; Moustaki 2023, Endocrine.

References

Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/

Arvat E, di Vito L, Maccagno B et al.. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997. https://pubmed.ncbi.nlm.nih.gov/9285939/

Arvat E, Di Vito L, Lanfranco F et al.. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans. J Endocrinol Invest. 1999. https://pubmed.ncbi.nlm.nih.gov/10195374/

de Sousa ME, Sousa LMM, List EO et al.. Low Liver-Derived IGF-1 Drives the Alterations in Growth Hormone Secretion in Food-Restricted Male Mice. Endocrinology. 2025. https://pubmed.ncbi.nlm.nih.gov/41058063/

Moustaki M, Paschou SA, Xekouki P et al.. Secondary diabetes mellitus in acromegaly. Endocrine. 2023. https://pubmed.ncbi.nlm.nih.gov/36882643/